PrioThera Limited’s €30 Million Series A Fundraising

Paolo Bossi

ByrneWallace advise PrioThera Limited (PrioThera) on the transaction. Priothera Limited, a clinical stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies,…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

…

This content is for Standard 1 Year members only.
Login Join Now